ArticleJournal of the American Society of Nephrology : JASN2026
Neutrophil Extracellular Traps Aggravate Injury in Complement-Mediated Thrombotic Microangiopathy.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
key pointsNeutrophil extracellular trap biomarkers were elevated and correlated with disease activity and complement deposition in thrombotic microangiopathy. Inhibiting neutrophil extracellular traps reduced organ injury and complement deposition through CD59 shedding in glomerular endothelial cells.
backgroundComplement hyperactivation and endothelial cell damage are pivotal pathogenic drivers of multiple organ damage in complement-mediated thrombotic microangiopathy (TMA). The specific pathogenic role of neutrophil extracellular traps (NETs) remains unclear.
methodsThis study included 107 patients with complement-mediated TMA and measured circulating and renal NET biomarkers. The effects of peptidylarginine deiminase 4 ( Pad4 ) knockout, NET inhibitors (deoxyribonuclease I or GSK484), and neutrophil depletion were evaluated for their ability to attenuate multiorgan injury in complement-mediated TMA mice with a point mutation (W1206R) in complement factor H (FH R/R ). Furthermore, the influence of NETs on the regulation of the membrane attack complex (MAC), with a focus on CD59 modulation, was investigated in cultured human renal glomerular endothelial cells (HRGECs) and human umbilical vein endothelial cells.
resultsElevated levels of NET biomarkers in both plasma and kidney tissues were observed in complement-mediated TMA patients, which were associated with disease activity and increased MAC deposition. In FH R/R mice, Pad4 knockout improved survival and attenuated phenotypes of TMA, as evidenced by the amelioration of anemia, kidney injury, MAC deposition, and macrovascular thrombosis. Therapeutic targeting of NETs with deoxyribonuclease I and PAD4 inhibitor GSK484 similarly ameliorated kidney pathology and MAC deposition in FH R/R mice. Neutrophil depletion significantly reduced systemic and kidney injury in FH R/R mice. NETs induced MAC deposition on HRGECs by promoting CD59 shedding through neutrophil serine proteases and enhanced coagulation through upregulation of tissue factor in human umbilical vein endothelial cells. Clinically, reduced glomerular CD59 expression and elevated urinary soluble CD59 levels were associated with both NET formation and MAC deposition.
conclusionsLevels of NET biomarkers increased in complement-mediated TMA and drove multiorgan injury by shedding CD59 from HRGECs to enhance complement activation and participate in coagulation activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.